News from eisai inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Apr 30, 2015, 10:09 ET

Eisai and Glenmark Reach Settlement over Generic Version of BANZEL® (rufinamide)

 Eisai Inc. and Eisai Co., Ltd. have entered into a settlement agreement with Glenmark Pharmaceuticals, Ltd., Glenmark Generics Ltd., and...

Apr 15, 2015, 08:00 ET

Helsinn Group and Eisai Inc. Announce Inclusion of AKYNZEO® (netupitant/palonosetron) in 2015 NCCN® Antiemesis Guidelines

 Helsinn Group and Eisai Inc. jointly announced today the decision of the National Comprehensive Cancer Network (NCCN) to include...

Apr 10, 2015, 08:00 ET
The first book in the ‘Medikidz Explain Epilepsy’ series, also available in Spanish

Eisai Launches New Book in Epilepsy Educational Comic Book Series Highlighting One Girl's Path from Patient to Advocate

 Eisai Inc. has teamed up with Medikidz USA Inc. to announce the availability of a third book, entitled "Medikidz Explain Living with...

Apr 09, 2015, 16:30 ET

Eisai Realigns U.S. Operations

 Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd., today announced plans to realign its operations in the United States. As part of this...

Mar 27, 2015, 11:20 ET

Lenvima® (Lenvatinib) erhält positive CHMP-Empfehlung nach signifikanten Phase-III-Daten zur Behandlung des fortgeschrittenen radiojod-refraktären differenzierten Schilddrüsenkarzinoms

NUR FÜR MEDIEN IN EU-LÄNDERN: NICHT FÜR MEDIEN AUS DER SCHWEIZ/DEN USA  Wie Eisai heute bekannt gibt, hat der Ausschuss...

Mar 27, 2015, 09:04 ET

Lenvatinib erhält positive CHMP-Empfehlung nach signifikanten Phase-III-Daten zur Behandlung des fortgeschrittenen radiojod-refraktären differenzierten Schilddrüsenkarzinoms

NUR FÜR MEDIEN IN EU-LÄNDERN: NICHT FÜR MEDIEN AUS DER SCHWEIZ/DEN USA Wie Eisai heute bekanntgibt, hat der Ausschuss für...

Mar 27, 2015, 08:39 ET
Mar 27, 2015, 08:25 ET
Mar 27, 2015, 08:00 ET

Lenvima® (lenvatinib) : avis favorable du CHMP dans le traitement du cancer de la thyroïde avancé réfractaire à l'iode radioactif

Eisai annonce aujourd'hui avoir reçu l'avis favorable du Comité des médicaments à usage humain (CHMP) pour son médicament...

Mar 04, 2015, 19:01 ET

Uno studio di fase III sull'agente antitumorale Halaven® (eribulina) nel sarcoma dei tessuti molli dimostra un beneficio nell'endpoint primario in termini di sopravvivenza complessiva

DESTINATO ESCLUSIVAMENTE ALLA STAMPA DELL'AREA EMEA: NON DESTINATO AI GIORNALISTI DI SVIZZERA/STATI UNITI  Eisai conferma il proprio impegno...

Mar 04, 2015, 19:01 ET
Mar 04, 2015, 19:01 ET

Un estudio fase III del agente antitumoral Halaven® (eribulina) en sarcoma de tejidos blandos demuestra un incremento de la supervivencia global como criterio de valoración principal

SOLO PARA LOS MEDIOS DE LA REGIÓN EMEA: NO PARA LOS MEDIOS SUIZOS/ESTADOUNIDENSES  Eisai demuestra su compromiso con los tipos de...

Mar 04, 2015, 19:01 ET

Phase-III-Studie des Krebsmedikaments Halaven®(Eribulin) bei Weichteilsarkomen zeigt positive Wirkung auf den primären Endpunkt "Gesamtüberleben"

PRESSEMITTEILUNG NUR FÜR EU-MEDIEN: NICHT FÜR JOURNALISTEN AUS DER SCHWEIZ/DEN USA  Eisai engagiert sich im Bereich der seltenen...

Feb 27, 2015, 08:05 ET
Eisai logo.

LENVIMA™ (lenvatinib) Now Available Through Two Specialty Pharmacies, Accredo and Biologics, Inc.

 Eisai Inc. announced today that LENVIMA™ (lenvatinib), a receptor tyrosine kinase inhibitor, is now available through two specialty...

Feb 25, 2015, 07:55 ET

Topline Results of Phase 3 Trial Show Eribulin Mesylate Injection Meets Primary Endpoint of Overall Survival in Advanced Soft Tissue Sarcoma

 Eisai Inc. today announced that eribulin met the primary endpoint in its Phase 3 trial (Study 309), demonstrating a statistically significant...

Feb 19, 2015, 07:55 ET

Eisai Launches BELVIQ® VOICES™, an Online Community of Personal Weight Loss Stories, Featuring Real Life Experiences with BELVIQ® (lorcaserin HCl) CIV

 Eisai Inc. today announced the launch of BELVIQ VOICES, an online community featuring real life weight loss journeys of patients living with...

Feb 17, 2015, 19:01 ET

ZONEGRAN® (ZONISAMIDE), traitement de l'épilepsie des laboratoires EISAI, autorisé en France chez l'enfant et l'adolescent

COMMUNIQUÉ DE PRESSE DESTINÉ AUX MÉDIAS EUROPÉENS UNIQUEMENT  La Commission de la Transparence de la Haute Autorité...

Feb 13, 2015, 19:39 ET
Feb 13, 2015, 15:55 ET

FDA Approves Eisai's LENVIMA™ (lenvatinib) for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer

 Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the company's receptor tyrosine kinase inhibitor...

Feb 13, 2015, 11:15 ET
Eisai logo

Eisai Announces FDA Approval of BANZEL® (rufinamide) for Adjunctive Treatment of Seizures Associated with Lennox-Gastaut Syndrome in Pediatric Patients Ages 1-4

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for...